Searching News Database: Vectibix
HSMN NewsFeed - 24 Oct 2024
Pillar Biosciences Receives CPT(R) Code for FDA Approved oncoReveal(TM) CDx Pan-Cancer Solid tumor IVD Kit
Pillar Biosciences Receives CPT(R) Code for FDA Approved oncoReveal(TM) CDx Pan-Cancer Solid tumor IVD Kit
HSMN NewsFeed - 15 Jul 2019
ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer
ESSA Expands Leadership Team by appointing Alessandra Cesano as Chief Medical Officer
HSMN NewsFeed - 22 Oct 2012
Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer
Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer
HSMN NewsFeed - 5 Nov 2009
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
HSMN NewsFeed - 31 May 2008
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
HSMN NewsFeed - 4 Feb 2008
Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates
Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates
HSMN NewsFeed - 5 Dec 2007
Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal Cancer
Vectibix(R) Approved in the European Union for the Treatment of Metastatic Colorectal Cancer
HSMN NewsFeed - 21 Sep 2007
Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union
Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union
HSMN NewsFeed - 27 Sep 2006
FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer
FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer